Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Provided By GlobeNewswire
Last update: Oct 6, 2025
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout
Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia
Read more at globenewswire.comNASDAQ:XCUR (12/3/2025, 8:02:43 PM)
5.56
+0.02 (+0.36%)
Find more stocks in the Stock Screener
